CN117357538A - 用于治疗肥胖症的雷公藤红素和衍生物 - Google Patents

用于治疗肥胖症的雷公藤红素和衍生物 Download PDF

Info

Publication number
CN117357538A
CN117357538A CN202311282376.1A CN202311282376A CN117357538A CN 117357538 A CN117357538 A CN 117357538A CN 202311282376 A CN202311282376 A CN 202311282376A CN 117357538 A CN117357538 A CN 117357538A
Authority
CN
China
Prior art keywords
compound
mice
alkyl
obese
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311282376.1A
Other languages
English (en)
Chinese (zh)
Inventor
R·马兹斯柴克
U·奥兹坎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Boston Childrens Hospital
Original Assignee
General Hospital Corp
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Boston Childrens Hospital filed Critical General Hospital Corp
Publication of CN117357538A publication Critical patent/CN117357538A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/38—Unsaturated compounds containing keto groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN202311282376.1A 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物 Pending CN117357538A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461970839P 2014-03-26 2014-03-26
US61/970,839 2014-03-26
PCT/US2015/022746 WO2015148802A1 (en) 2014-03-26 2015-03-26 Celastrol and derivatives for the treatment of obesity
CN201580027586.3A CN107073016A (zh) 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580027586.3A Division CN107073016A (zh) 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物

Publications (1)

Publication Number Publication Date
CN117357538A true CN117357538A (zh) 2024-01-09

Family

ID=52823863

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580027586.3A Pending CN107073016A (zh) 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物
CN202311282376.1A Pending CN117357538A (zh) 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201580027586.3A Pending CN107073016A (zh) 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物

Country Status (10)

Country Link
US (3) US20150274634A1 (enExample)
EP (1) EP3122347B1 (enExample)
JP (1) JP2017513824A (enExample)
CN (2) CN107073016A (enExample)
AU (2) AU2015235979B2 (enExample)
BR (1) BR112016021985B1 (enExample)
CA (2) CA2944030C (enExample)
ES (1) ES2813424T3 (enExample)
RU (1) RU2706239C2 (enExample)
WO (1) WO2015148802A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117860904A (zh) * 2024-01-10 2024-04-12 四川大学 一种四面体框架核酸-雷公藤红素复合物及其制备方法和应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3431615A3 (en) 2007-10-19 2019-02-20 The Trustees of Columbia University in the City of New York Dna sequencing with non-fluorescent nucleotide reversible terminators cleavable label modified nucleotide terminators
WO2015153933A1 (en) * 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
MA45430A (fr) * 2015-10-23 2019-05-01 Erx Pharmaceuticals Inc Analogues de célastrol
US10053693B2 (en) 2016-01-19 2018-08-21 Mubin I. Syed Method for controlling obesity using minimally invasive means
CN109803664A (zh) * 2016-06-15 2019-05-24 尚特·德扎尔基西安 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法
WO2018006804A1 (zh) * 2016-07-04 2018-01-11 厦门大学 孤儿核受体Nur77的配体及其用途
CN106243181A (zh) * 2016-07-29 2016-12-21 合肥中科玛卡生物技术有限公司 一种从苦瓜中提取雷公藤红素的方法
WO2018026810A1 (en) * 2016-08-03 2018-02-08 Vanderbilt University Treatment methods using celastrol
CN111821308B (zh) * 2019-04-15 2021-10-08 中国科学院上海药物研究所 雷藤舒在制备用于治疗非酒精性脂肪性肝病的药物中的应用
US20220324903A1 (en) * 2019-09-12 2022-10-13 Nucmito Pharmaceuticals Company Limited Triterpenoid compounds, pharmaceutical compositions thereof, and their use for treating a nuclear receptor subfamily 4 group a member 1-mediated disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
JP2006508182A (ja) * 2002-10-21 2006-03-09 メタプロテオミクス， エルエルシー 炎症応答と関連した病理学的状態を処置または抑制する組成物。
US8236769B2 (en) * 2005-09-30 2012-08-07 Morinaga Milk Industry Co., Ltd. Agent for improving insulin resistance
US20100240581A1 (en) * 2006-11-13 2010-09-23 The Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
US8641155B2 (en) * 2007-07-26 2014-02-04 David Lee Modular furniture system
US7776894B2 (en) * 2007-08-17 2010-08-17 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CN101434635B (zh) * 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
AU2009332930A1 (en) * 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
WO2010119674A1 (ja) * 2009-04-17 2010-10-21 国立大学法人広島大学 レプチン抵抗性を改善および／または予防するための薬学的組成物、並びにその使用
CN102574890B (zh) * 2010-08-23 2015-03-11 苏州润新生物科技有限公司 某些化学个体、组合物及方法
TWI576347B (zh) * 2012-01-20 2017-04-01 艾克泰聯製藥有限公司 作為ｐ２ｘ受體拮抗劑之雜環醯胺衍生物
BR112014029301A2 (pt) * 2012-05-25 2017-07-25 Berg Llc métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta
RU2650646C2 (ru) * 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
CN103524592B (zh) * 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117860904A (zh) * 2024-01-10 2024-04-12 四川大学 一种四面体框架核酸-雷公藤红素复合物及其制备方法和应用

Also Published As

Publication number Publication date
US20150274634A1 (en) 2015-10-01
AU2015235979A1 (en) 2016-10-20
JP2017513824A (ja) 2017-06-01
AU2015235979B2 (en) 2019-05-02
US20190062254A1 (en) 2019-02-28
ES2813424T3 (es) 2021-03-23
CN107073016A (zh) 2017-08-18
RU2706239C2 (ru) 2019-11-15
BR112016021985A8 (pt) 2021-06-29
CA2944030C (en) 2019-06-04
RU2016141567A3 (enExample) 2018-04-27
CA2944030A1 (en) 2015-10-01
RU2016141567A (ru) 2018-04-27
CA3044998A1 (en) 2015-10-01
WO2015148802A1 (en) 2015-10-01
EP3122347A1 (en) 2017-02-01
AU2019202601A1 (en) 2019-05-02
BR112016021985B1 (pt) 2022-08-30
US20180194709A1 (en) 2018-07-12
BR112016021985A2 (pt) 2017-08-15
EP3122347B1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
CN117357538A (zh) 用于治疗肥胖症的雷公藤红素和衍生物
US12064408B2 (en) Compounds for the treatment of obesity and methods of use thereof
AU2014354831B2 (en) Compounds for the treatment of obesity and methods of use thereof
HK40083451A (en) Compounds for the treatment of obesity and methods of use thereof
HK40034039A (en) Compounds for the treatment of obesity and methods of use thereof
HK40034040A (en) Compounds for the treatment of obesity and methods of use thereof
HK1233923A1 (en) Celastrol derivatives for the treatment of obesity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination